Despite strong growth, Silence Therapeutics' high P/S ratio ...
Despite strong growth, Silence Therapeutics' high P/S ratio and weak revenue outlook suggest a risk of share price decline. Analysts lack confidence in a business turnaround, indicating potential risk for shareholders and potential investors.
Optimistic Investors Push Silence Therapeutics Plc (NASDAQ:SLN) Shares Up 26% But Growth Is Lacking
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment